A new biotech from a long­time de­vel­op­er wants to bring the tar­get­ed can­cer rev­o­lu­tion to the kids left be­hind

Daphne Haas-Ko­gan was treat­ing and study­ing chil­dren’s brain tu­mors at the Uni­ver­si­ty of Cal­i­for­nia San-Fran­cis­co, when she got a call that shook her. The phar­ma com­pa­ny whose drug she had been prep­ping for a tri­al had de­cid­ed, de­spite all pre­clin­i­cal ev­i­dence, to not run any tri­als on kids, on­ly adults. Haas-Ko­gan’s pa­tients would not get the ther­a­py.

“Ul­ti­mate­ly the com­pa­ny had to make a de­ci­sion for what tri­als they would sup­port,” Haas-Ko­gan said. “I can still re­call my blood pres­sure ris­ing as I found out.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER